Search Results

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease following approvals for ulcerative colitis. GlobalData projects total sales for Tremfya to reach $7.8 billion globally by 2029.

Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn’s & Colitis Foundation (the “Foundation”) as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn’s disease and ulcerative colitis.

Geneoscopy, Inc. will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Palisade Bio, Inc. today announced that it presented at IBD Innovate: Product Development for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA.

Palisade Bio, Inc. announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program.

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.

Palisade Bio, Inc. today announced the presentation of positive preclinical data of its lead asset, PALI-2108 at the Crohn’s & Colitis Congress, which was held on January 25-27, 2024 in Las Vegas, NV.

Organovo Holdings, Inc. (NASDAQ: ONVO) based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.